Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry

• US 20070128731A1
• Filed: 12/06/2006
• Published: 06/07/2007
• Est. Priority Date: 12/07/2005
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Mirmehrabi, Mahmoud, Deshmukh, Subodh
• Application Number:
  US11/634,694
• Publication Number:
  US 20070128731A1
• Time in Patent Office: Days
• US Class Current: 436/147
• CPC Class Codes: C07D 498/14 Ortho-condensed systems
• CPC Class Codes: C07D 498/18 Bridged systems
• CPC Class Codes: C07H 17/08 Hetero rings containing eight or more ring members, e.g. erythromycins
• CPC Class Codes: G01N 25/4866 by using a differential method

Abstract

Methods for purifying rapamycin are described. Methods for measuring particle quality, median particle size, and crystallinity of samples containing rapamycin or a derivative thereof are also provided.

Claims

1. A method for measuring particle quality of a rapamycin compound using differential scanning calorimetry, comprising:

analyzing the heat flow signal of a sample comprising a rapamycin compound; and

comparing the heat flow signal of said sample to the heat flow signal of a predetermined standard;

wherein said particle quality is proportional to the melting temperature of said heat flow signal of said sample.

2. The method according to claim 1, wherein a higher melting temperature corresponds to a higher quality particle.

3. The method according to claim 2, wherein a higher particle quality corresponds to a higher crystallinity of said rapamycin compound.

4. The method according to claim 1, wherein said melting temperature is proportional to the median particle size of the crystals of said rapamycin compound.

5. The method according to claim 4, wherein a large median particle size is characterized by a high melting temperature.

6. The method according to claim 5, wherein said sample comprises CCI-779 and said large median particle size is at least about 30 μ

m.

7. The method according to claim 6, wherein said large median particle size is about 30 μ

m to about 250 μ

m.

8. The method according to claim 5, wherein said sample comprises CCI-779 and said high melting temperature is at least about 168°

C.

9. The method according to claim 8, wherein said high melting temperature is about 168 to about 170°

C.

10. The method according to claim 5, wherein said sample comprises rapamycin and said high melting temperature is at least about 188°

C.

11. The method according to claim 10, wherein said high melting temperature is about 188°

C. to about 190°

C.

12. The method according to claim 1, wherein a small median particle size of the crystals of said rapamycin compound is characterized by a low melting temperature.

13. The method according to claim 12, wherein said sample comprises CCI-779 and said small median particle size is less than about 30 μ

m.

14. The method according to claim 1, wherein a lower melting temperature corresponds to a lower quality particle.

15. The method according to claim 14, wherein a lower particle quality corresponds to a lower crystallinity.

16. The method according to claim 14, wherein said sample comprises CCI-779 and said low melting temperature is less than about 166°

C.

17. The method according to claim 16, wherein said low melting temperature is about 164 to about 166°

C.

18. The method according to claim 14, wherein said sample comprises rapamycin and said low melting temperature is less than about 183°

C.

19. The method according to claim 14, wherein said sample comprises rapamycin and said low melting temperature is less than about 180 to about 183°

C.

20. The method according to claim 1, wherein said sample comprises semi-crystalline aggregates and has a lower melting temperature than a crystalline sample.

21. The method according to claim 1, wherein said sample comprises a non-crystalline rapamycin compound and has a lower melting temperature than a sample comprising a semi-crystalline rapamycin compound.

22. The method according to claim 1, wherein said sample comprising a non-crystalline rapamycin compound and has a lower melting temperature than a sample comprising a crystalline rapamycin compound.

23. The method according to claim 1, wherein said rapamycin compound is purified from the same solvent as the predetermined standard.

24. The method according to claim 1, wherein said sample comprises rapamycin.

25. The method according to claim 1, wherein said sample comprises CCI-779.

26. A method for determining median particle size of a sample containing crystals of a rapamycin compound using differential scanning calorimetry, comprising:

analyzing the melting temperature of a sample comprising a rapamycin compound; and

comparing the melting temperature to a predetermined standard;

wherein said median particle size is proportional to the melting temperature of said sample.

27. The method according to claim 26, wherein a large median particle size is characterized by a high melting temperature and a small median particle size is characterized to a low melting temperature.

28. A method for determining the crystallinity of a rapamycin compound, comprising:

analyzing the heat flow signal of a test sample comprising a raparnycin compound; and

calculating the crystallinity of said test sample by comparing said heat flow signal to the heat flow signal of a predetermined standard comprising a crystalline rapamycin compound.

29. The method according to claim 28, wherein said calculation is performed using a single point calculation.

30. The method according to claim 29, wherein said predetermined standard comprises a 100% crystalline rapamycin compound.

31. The method according to claim 30, wherein said crystallinity of said test sample is calculated according to the following:

test sample crystallinity=100×

heat of fusion of said test sample/heat of fusion of said predetermined standard.

32. The method according to claim 28, wherein said calculation is performed using a calibration curve.

33. The method according to claim 32, wherein said predetermined standard comprises multiple samples comprising crystalline rapamycin compound.

34. The method according to claim 33, further comprising:

plotting the heat of fusion, peak temperature, or onset temperature for each of said multiple samples against the crystallinity of each of said multiple samples to obtain a calibration curve having a best fit line;

calculating a formula of said best fit line;

analyzing the heat of fusion, peak temperature, or onset temperature of said rapamycin compound in said test sample; and

calculating the crystallinity of said rapamycin compound in said test sample using said heat of fusion, peak temperature, or onset temperature of said test sample and said formula.

35. The method according to claim 33, wherein said calibration curve is prepared by plotting said heat of fusion for each of multiple samples comprising a crystalline rapamycin compound of a known crystallinity against the crystallinity for each of multiple samples comprising said rapamycin compound.

36. A method for purifying rapamycin, comprising:

(i) heating crude rapamycin in ethyl acetate to about 55°

C.;

(ii) filtering the product of step (i);

(iii) maintaining the temperature of step (ii) at about 54°

C. to about 57°

C.;

(iv) adding heptanes to the product of step (iii) over a period of about 60 minutes at a constant rate;

(v) maintaining the product of step (iv) at said temperature for about 30 minutes;

(vi) reducing the agitation speed of step (v);

(vii) cooling the product of step (vi) to about 40°

C. at a rate of about 5°

C./hour;

(viii) cooling the product of step (vii) to a temperature of about 25°

C. at a rate of about 7.5°

C./hour;

(ix) cooling the product of step (viii) to a temperature of about 7 to 8°

C. at a rate of at least about 9°

C./hour;

(x) maintaining the product of step (ix) at said temperature for about 2 hours; and

(xi) filtering the product of step (x) to obtain said crystalline rapamycin.

37. The method according to claim 36, further comprising:

(xii) washing said crystalline rapamycin with ethyl acetate and heptane at about 8°

C.; and

(xiii) drying the product of step (xii).